Composition: eachvial contains:
active substance: cytarabine – 1000 mg, 100 mg.
- Lymphoblast and myeloblast leukemia.
- Chronic myeloleukemia.
- Erythroleukemia, lymphogranulomatosis.
- Non-Hodgkin’s lymphoma.
- Syndrome of bone marrow dysplasia.
The Cytarabine high-dose therapy is applied within the induction and consolidation programs under primary acute lymphoblast and myeloblast leukemia; under secondary leukemia developed either after the preceding cytostatic and/or beam therapy or as a result of the MDS transformation; under primarily resistant forms of acute leukemia; under resistant relapses of acute leukemia; under a blast crisis of chronic myeloleukemia; under resistant forms of highly malignant Hodgkin’s and non-Hodgkin’s lymphomas.
lyophilized powder for solution for injection / solution for injection 20 mg/ml
Store in protected from light place at temperature below 25°C.